Home>Topics>Stocks>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Dendreon : Is The End Near?

    Headlines

    Wed, 13 Aug 2014

    By Alexander Maxwell: Dendreon Corporation (NASDAQ: DNDN ) shareholders got a piece of ..... sent the stock tumbling. Dendreon is not likely to have enough ..... will set off a showdown between Dendreon and its note holders sometime

  2. Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

    Headlines

    Tue, 12 Aug 2014

    alongside chemotherapy, surgery, and radiation. Investors associate cancer immunotherapy with forerunner Dendreon Corporation (NASDAQ: DNDN ), whose PROVENGE vaccine shocked health plans with its exorbitant price that only extended life a few

  3. More on Dendreon Q2 results

    Headlines

    Tue, 12 Aug 2014

    Dendreon ( DNDN -33.5% ) Q2 results : Revenues: $82.2M (+12.1%); Operating Expenses: $83.9M (-34.7%); Net Loss

  4. Dendreon Provides A Major Warning To Shareholders

    Headlines

    Tue, 12 Aug 2014

    By Bill Maurer : I've spent a lot of time detailing the short thesis for biotech name Dendreon (NASDAQ: DNDN ). Shares of the company have continued to plunge, and closed at just $2.12 yesterday. With the company in a period of executive

  5. Dendreon beats by $0.10, revenue in-line

    Headlines

    Tue, 12 Aug 2014

    Dendreon (NASDAQ: DNDN ): Q2 EPS of -$0.10 beats by $0.10 . Revenue of $82.2M (+12.1% Y/Y) in-line. Shares -22.6% PM. Press Release Post your comment!

  6. New Morningstar Analyst Report for Seattle Genetics Inc

    Stock Reports

    Fri, 1 Aug 2014

    in the investment community (given the recent failure of Dendreon 's pricey prostate cancer drug to live up to sales expectations ..... in the investment community following the recent failure of Dendreon 's DNDN pricey prostate cancer drug Provenge to live up to sales expectations

  7. 3 Convincing Reasons To Buy Dendreon

    Headlines

    Thu, 24 Jul 2014

    By Renu Singh : Biotechnology company Dendreon (NASDAQ: DNDN ) is not in good health in 2014. The ..... marginally better as compared to last year. Dendreon 's cancer drug, Provenge, turned in ..... in half from the year-ago period, Dendreon shares fell. But, on a year-over

  8. New Provenge Data: Why Deerfield Investments Acquired A More Than 5% Stake In May

    Headlines

    Mon, 7 Jul 2014

    By PR Research : Followers of Dendreon ( DNDN ) may have noticed that since May, the ..... is a discussion for another time). Dendreon stock has now approached the upper trendline ..... click to enlarge) Option trading in DNDN has seen some accumulation of July 2

  9. What Does Dendreon Need To Succeed?

    Headlines

    Mon, 7 Jul 2014

    By Bill Maurer : I know that my coverage of biotech Dendreon ( DNDN ) has been heavily slanted towards the negative side ..... shares back from their 52-week low of $1.81. For Dendreon , there is still hope, although the picture may not

  10. Dendreon Receives Positive EU Opinion for Provenge; No Change to Fair Value Estimate or Moat Rating

    Commentary

    Fri, 28 Jun 2013

    Dendreon DNDN announced that it received a positive ..... Commission later this year, and we expect Dendreon to announce its commercialization plans ..... rating intact as we remain concerned about Dendreon 's ability to achieve meaningful commercial

« Prev1234Next »
Content Partners